Immunocore Holdings Investor Relations Material
Latest events
Q2 2025
Immunocore Holdings
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Immunocore Holdings plc
Access all reports
Immunocore Holdings plc is a commercial-stage biotechnology company focused on the development of innovative immunotherapies for cancer, infectious diseases, and autoimmune diseases. Utilizing its proprietary T cell receptor (TCR) technology, the company aims to create transformative medicines to address unmet medical needs. Among its notable products is KIMMTRAK, designed for the treatment of patients with unresectable or metastatic uveal melanoma. Immunocore is headquartered in Abingdon, the United Kingdom, and is listed on the NASDAQ stock exchange under the ticker symbol IMCR.
Key slides for Immunocore Holdings plc
Q2 2025
Immunocore Holdings plc
Q2 2025
Immunocore Holdings plc
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
IMCR
Country
🇺🇸 United States